<DOC>
	<DOCNO>NCT01474642</DOCNO>
	<brief_summary>Until today , 5-FU/cisplatin combination reference regimen 30-45 % response rate , commonly use treat patient metastatic , recurrent locally advanced , unresectable squamous cell carcinoma esophagus . Because classical dose schedule two-drug combination cisplatin 100 mg/m2 day 1 5-FU 1000 mg/m2/day continuous infusion 96-120 hr , prolonged administration time mucosal toxicity inconvenient patient aim palliation . Capecitabine , oral prodrug 5-FU mimic continuously-infused 5-FU , investigated phase I , II III trial treatment gastric , gastroesophageal , esophageal cancer , primarily first-line metastatic setting also adjuvant set . In investigator experience , capecitabine plus cisplatin combination ( XP ) first-line treatment 45 patient advanced recurrent esophageal squamous cell carcinoma demonstrate promising anti-tumor activity 57 % response rate show tolerable toxicity convenience . Paclitaxel also investigate monotherapy combination cisplatin patient advanced esophageal cancer . A Dutch phase II study demonstrate paclitaxel combination carboplatin show encourage confirm response rate 59 % 51 patient resectable esophageal cancer neoadjuvant setting . Another Dutch phase II study show 43 % response rate include 4 % CR 8 month response duration paclitaxel plus cisplatin administration give patient metastatic esophageal cancer . Although recently first-line palliative chemotherapy regimen esophageal cancer investigate , many trial fail show superiority 5-FU/cisplatin combination . Since investigator consider XP XG ( genexol ) effective convenient chemotherapy regimen 5-FU/cisplatin , randomized phase II study plan compare XP XG term efficacy tolerability .</brief_summary>
	<brief_title>Phase II Trial XP Versus XG Advanced Esophageal Squamous Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Inclusion Criteria Histologically confirm metastatic , recurrent esophageal squamous cell carcinoma Age &gt; 18 year ECOG performance status 0 2 At least one measurable lesion ( ) RECIST criteria Life expectancy ≥ 3 month No prior palliative chemotherapy Patients may receive prior adjuvant chemotherapy 5FU cisplatin long 6months since completion regimen . Adequate bone marrow function ( ≥ ANC 1,500/ul , ≥ platelet 100,000/ul , ≥ Hb 9.0 g/dl ) Adequate renal function ( ≤ serum creatinine 1.5 mg/dl CCr ≥ 50 ml/min ) Adequate liver function ( ≤ serum bilirubin 1.5 mg/dl , ≤ AST/ALT x 3 UNL ) Written inform consent Other tumor type squamous cell carcinoma CNS metastasis Contraindication drug contain chemotherapy regimen Previous adjuvant treatment 5FU , cisplstin , capecitabine paclitaxel finish less 1 year6 month Evidence serious gastrointestinal bleeding History another malignancy within last five year except cure basal cell carcinoma skin cure carcinoma insitu uterine cervix Clinically significant cardiac disease Serious pulmonary conditions/illness Serious metabolic disease severe noncompensated diabetes mellitus History significant neurologic psychiatric disorder Serious uncontrolled intercurrent infection , serious uncontrolled concomitant disease Positive serology HIV Pregnancy , breast feeding patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Advanced recurrent esophageal squamous cell carcinoma</keyword>
	<keyword>Randomizes phase II trial</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Genexol</keyword>
</DOC>